BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innovation Showcase

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress and cash position (unaudited) for the second quarter of 2021.

Q-State Biosciences (“Q-State”), today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain

Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC).

The solvent evaporation market was valued at US$ 470.77 million in 2020 and it is projected to reach US$ 821.41 million by 2028; it is expected to grow at a CAGR of 6.7% during 2021–2028.

The medical perfusion technology market is expected to reach US$ 962.60 million by 2027 from US$ 707.10 million in 2019. The market is estimated to grow at a CAGR of 4.1% from 2020 to 2027.

The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.

Scilex Holding Company (“Scilex”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced complete enrollment of SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica.